NI201000185A - Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer. - Google Patents

Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer.

Info

Publication number
NI201000185A
NI201000185A NI201000185A NI201000185A NI201000185A NI 201000185 A NI201000185 A NI 201000185A NI 201000185 A NI201000185 A NI 201000185A NI 201000185 A NI201000185 A NI 201000185A NI 201000185 A NI201000185 A NI 201000185A
Authority
NI
Nicaragua
Prior art keywords
cancer
releasing factor
treatment
methods
corticotropin releasing
Prior art date
Application number
NI201000185A
Other languages
English (en)
Spanish (es)
Inventor
Evans-Freke Stephen
Original Assignee
Neutron Row
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Row filed Critical Neutron Row
Publication of NI201000185A publication Critical patent/NI201000185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NI201000185A 2008-04-30 2010-10-28 Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer. NI201000185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US9480608P 2008-09-05 2008-09-05

Publications (1)

Publication Number Publication Date
NI201000185A true NI201000185A (es) 2013-04-22

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000185A NI201000185A (es) 2008-04-30 2010-10-28 Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer.

Country Status (17)

Country Link
US (1) US20100113341A1 (enExample)
EP (1) EP2259793A2 (enExample)
JP (1) JP2011519375A (enExample)
KR (1) KR20110021820A (enExample)
CN (1) CN102036680A (enExample)
AU (1) AU2009241813A1 (enExample)
CA (1) CA2722426A1 (enExample)
CO (1) CO6300959A2 (enExample)
CR (1) CR11762A (enExample)
EC (1) ECSP10010631A (enExample)
IL (1) IL209005A0 (enExample)
MX (1) MX2010011882A (enExample)
NI (1) NI201000185A (enExample)
NZ (1) NZ588877A (enExample)
RU (1) RU2010148803A (enExample)
WO (1) WO2009134396A2 (enExample)
ZA (1) ZA201007729B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
KR20120124353A (ko) * 2009-06-24 2012-11-13 스티븐 에반스-프레케 암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
WO1984001378A1 (en) 1982-09-29 1984-04-12 Karl P Lederis Urotensin peptides
US4528189A (en) * 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子－12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
KR101235723B1 (ko) * 2004-07-08 2013-02-21 아임스코 리미티드 약제
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Also Published As

Publication number Publication date
US20100113341A1 (en) 2010-05-06
CA2722426A1 (en) 2009-11-05
AU2009241813A1 (en) 2009-11-05
IL209005A0 (en) 2011-01-31
CR11762A (es) 2011-04-26
RU2010148803A (ru) 2012-06-10
ECSP10010631A (es) 2011-02-28
WO2009134396A2 (en) 2009-11-05
EP2259793A2 (en) 2010-12-15
JP2011519375A (ja) 2011-07-07
NZ588877A (en) 2012-08-31
CO6300959A2 (es) 2011-07-21
WO2009134396A3 (en) 2010-04-15
CN102036680A (zh) 2011-04-27
KR20110021820A (ko) 2011-03-04
MX2010011882A (es) 2011-02-25
ZA201007729B (en) 2014-02-26

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX2010004074A (es) Combinacion 059.
AR062522A1 (es) Tratamiento de desordenes en cartilagos
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
MX2020009773A (es) Terapia de combinacion.
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
NI201000185A (es) Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer.
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
NO20064754L (no) Kombinasjonsterapi
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
AR073585A1 (es) Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie